Hormonal Mechanisms Underlying the Relationship Between Obesity and Breast Cancer

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 485-507

  Perks, Claire M ^a   Holly, Jeff M P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Adipokines; Breast cancer; Estrogen receptor; IGFs; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GHRELIN; GLUCOCORTICOID; INSULIN; INTERLEUKIN 6; LEPTIN; LETROZOLE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OBESTATIN; PEGYLATED LEPTIN PEPTIDE RECEPTOR ANTAGONIST; SCATTER FACTOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CALORIC RESTRICTION; CANCER RISK; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DRUG TARGETING; EPIDEMIC; FAMILY HISTORY; HIGH RISK POPULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; KINESIOTHERAPY; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TREND STUDY;

ADIPOKINES; ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; OBESITY; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RISK FACTORS; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 80052192474     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.010     Document Type: Review

References (201)

1. Ogden C.L., Carroll M.D., McDowell M.A., et al. Obesity among adults in the United States-no statistically significant chance since 2003-2004. NCHS Data Brief 2007, (1):1-8.
2. Flegal K.M. Epidemiologic aspects of overweight and obesity in the United States. Physiol Behav 2005, 86(5):599-602.
3. Finkelstein E.A., Trogdon J.G., Cohen J.W., et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009, 28(5):w822-w831.
4. Michels K.B., Trichopoulos D., Robins J.M., et al. Birthweight as a risk factor for breast cancer. Lancet 1996, 348(9041):1542-1546.
5. dos Santos Silva I., De Stavola B.L., Hardy R.J., et al. Is the association of birth weight with premenopausal breast cancer risk mediated through childhood growth?. Br J Cancer 2004, 91(3):519-524.
6. Andersson S.W., Bengtsson C., Hallberg L., et al. Cancer risk in Swedish women: the relation to size at birth. Br J Cancer 2001, 84(9):1193-1198.
7. Hubinette A., Lichtenstein P., Ekbom A., et al. Birth characteristics and breast cancer risk: a study among like-sexed twins. Int J Cancer 2001, 91(2):248-251.
8. Schernhammer E.S., Tworoger S.S., Eliassen A.H., et al. Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 2007, 14(3):721-732.
9. Boyne M.S., Thame M., Bennett F.I., et al. The relationship among circulating insulin-like growth factor (IGF)-I, IGF-binding proteins-1 and -2, and birth anthropometry: a prospective study. J Clin Endocrinol Metab 2003, 88(4):1687-1691.
10. Vatten L.J., Maehle B.O., Lund Nilsen T.I., et al. Birth weight as a predictor of breast cancer: a case-control study in Norway. Br J Cancer 2002, 86(1):89-91.
11. Bardia A., Vachon C.M., Olson J.E., et al. Relative weight at age 12 and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(2):374-378.
12. Michels K.B., Terry K.L., Willett W.C. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med 2006, 166(21):2395-2402.
13. Baer H.J., Tworoger S.S., Hankinson S.E., et al. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol 2010, 171(11):1183-1194.
14. van den Brandt P.A., Spiegelman D., Yaun S.S., et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000, 152(6):514-527.
15. Reeves G.K., Pirie K., Beral V., et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007, 335(7630):1134.
16. Barnett G.C., Shah M., Redman K., et al. Risk factors for the incidence of breast cancer: do they affect survival from the disease?. J Clin Oncol 2008, 26(20):3310-3316.
17. Dal Maso L., Zucchetto A., Talamini R., et al. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer 2008, 123(9):2188-2194.
18. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348(17):1625-1638.
19. Kwan M.L., Kushi L.H., Weltzien E., et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009, 11(3):R31.
20. Berclaz G., Li S., Price K.N., et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004, 15(6):875-884.
21. Feigelson H.S., Patel A.V., Teras L.R., et al. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer 2006, 107(1):12-21.
22. Carpenter C.L., Ross R.K., Paganini-Hill A., et al. Effect of family history, obesity and exercise on breast cancer risk among postmenopausal women. Int J Cancer 2003, 106(1):96-102.
23. Nkondjock A., Robidoux A., Paredes Y., et al. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat 2006, 98(3):285-294.
24. Martin R.M., Holly J.M., Middleton N., et al. Childhood diet and insulin-like growth factors in adulthood: 65-year follow-up of the Boyd Orr Cohort. Eur J Clin Nutr 2007, 61(11):1281-1292.
25. Martin R.M., Holly J.M., Davey Smith G., et al. Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr Cohort. J Clin Endocrinol Metab 2006, 91(9):3287-3295.
26. Mangelsdorf D.J., Thummel C., Beato M., et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83(6):835-839.
27. Nilsson S., Makela S., Treuter E., et al. Mechanisms of estrogen action. Physiol Rev 2001, 81(4):1535-1565.
28. Fox E.M., Davis R.J., Shupnik M.A. ERbeta in breast cancer-onlooker, passive player, or active protector?. Steroids 2008, 73(11):1039-1051.
29. Fuqua S.A. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2001, 6(4):407-417.
30. Hartman J., Strom A., Gustafsson J.A. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids 2009, 74(8):635-641.
31. Siiteri P.K. Adipose tissue as a source of hormones. Am J Clin Nutr 1987, 45(Suppl 1):277-282.
32. Miller W.R. Aromatase and the breast: regulation and clinical aspects. Maturitas 2006, 54(4):335-341.
33. Lonning P.E., Helle H., Duong N.K., et al. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009, 117(1-3):31-41.
34. Chand A.L., Simpson E.R., Clyne C.D. Aromatase expression is increased in BRCA1 mutation carriers. BMC Cancer 2009, 9:148.
35. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998, 19(1):1-27.
36. Holly J.M., Smith C.P., Dunger D.B., et al. Relationship between the pubertal fall in sex hormone binding globulin and insulin-like growth factor binding protein-I. A synchronized approach to pubertal development?. Clin Endocrinol (Oxf) 1989, 31(3):277-284.
37. Weaver J.U., Holly J.M., Kopelman P.G., et al. Decreased sex hormone binding globulin (SHBG) and insulin-like growth factor binding protein (IGFBP-1) in extreme obesity. Clin Endocrinol (Oxf) 1990, 33(3):415-422.
38. McTiernan A., Wu L., Chen C., et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring) 2006, 14(9):1662-1677.
39. Yager J.D., Davidson N.E. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354(3):270-282.
40. Vona-Davis L., Rose D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007, 14(2):189-206.
41. Key T., Appleby P., Barnes I., et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94(8):606-616.
42. Hankinson S.E., Willett W.C., Manson J.E., et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998, 90(17):1292-1299.
43. Kaaks R., Rinaldi S., Key T.J., et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005, 12(4):1071-1082.
44. Lonning P.E. Aromatase inhibition for breast cancer treatment. Acta Oncol 1996, 35(Suppl 5):38-43.
45. Hankinson S.E., Willett W.C., Manson J.E., et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995, 87(17):1297-1302.
46. Bezemer I.D., Rinaldi S., Dossus L., et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2005, 16(5):561-572.
47. Cento R.M., Proto C., Spada R.S., et al. Leptin levels in menopause: effect of estrogen replacement therapy. Horm Res 1999, 52(6):269-273.
48. Eliassen A.H., Missmer S.A., Tworoger S.S., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98(19):1406-1415.
49. Perks C.M., Holly J.M. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia 2008, 13(4):455-469.
50. Belfiore A., Frasca F., Pandini G., et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009, 30(6):586-623.
51. Grundy S.M. What is the contribution of obesity to the metabolic syndrome?. Endocrinol Metab Clin North Am 2004, 33(2):267-282.
52. Godden J., Leake R., Kerr D.J. The response of breast cancer cells to steroid and peptide growth factors. Anticancer Res 1992, 12(5):1683-1688.
53. De Leon D.D., Wilson D.M., Powers M., et al. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors 1992, 6(4):327-336.
54. Taylor A.M., Dunger D.B., Preece M.A., et al. The growth hormone independent insulin-like growth factor-I binding protein BP-28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetics. Clin Endocrinol (Oxf) 1990, 32(2):229-239.
55. Mawson A., Lai A., Carroll J.S., et al. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 2005, 229(1-2):161-173.
56. Baxter R.C., Brown A.S., Turtle J.R. Association between serum insulin, serum somatomedin and liver receptors for human growth hormone in streptozotocin diabetes. Horm Metab Res 1980, 12(8):377-381.
57. Lukanova A., Lundin E., Zeleniuch-Jacquotte A., et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 2004, 150(2):161-171.
58. Allen N.E., Appleby P.N., Kaaks R., et al. Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 2003, 14(1):65-74.
59. Key T.J., Appleby P.N., Reeves G.K., et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010, 11(6):530-542.
60. Valentinis B., Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001, 54(3):133-137.
61. Peruzzi F., Prisco M., Dews M., et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999, 19(10):7203-7215.
62. Mauro L., Salerno M., Morelli C., et al. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J Cell Physiol 2003, 194(2):108-116.
63. Doerr M.E., Jones J.I. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996, 271(5):2443-2447.
64. Guvakova M.A., Adams J.C., Boettiger D. Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci 2002, 115(Pt 21):4149-4165.
65. Darcy K.M., Shoemaker S.F., Lee P.P., et al. Hydrocortisone and progesterone regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture. J Cell Physiol 1995, 163(2):365-379.
66. Lyons W.R. Hormonal synergism in mammary growth. Proc R Soc Lond B Biol Sci 1958, 149(936):303-325.
67. Goya L., Maiyar A.C., Ge Y., et al. Glucocorticoids induce a G1/G0 cell cycle arrest of Con8 rat mammary tumor cells that is synchronously reversed by steroid withdrawal or addition of transforming growth factor-alpha. Mol Endocrinol 1993, 7(9):1121-1132.
68. Gong H., Jarzynka M.J., Cole T.J., et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res 2008, 68(18):7386-7393.
69. Pang D., Kocherginsky M., Krausz T., et al. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 2006, 5(8):933-940.
70. Lu L., Zhao G., Luu-The V., et al. Expression of 11beta-hydroxysteroid Dehydrogenase Type 1 in Breast cancer and adjacent non-malignant tissue. An Immunocytochemical Study. Pathol Oncol Res 2011, [Epub ahead of print].
71. Feigelson H.S., Teras L.R., Diver W.R., et al. Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res 2008, 10(4):R57.
72. Beato M., Herrlich P., Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83(6):851-857.
73. Lien H.C., Lu Y.S., Cheng A.L., et al. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol 2006, 209(3):317-327.
74. Rask E., Walker B.R., Soderberg S., et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002, 87(7):3330-3336.
75. Stimson R.H., Walker B.R. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Minerva Endocrinol 2007, 32(3):141-159.
76. Gualillo O., Lago F., Casanueva F.F., et al. One ancestor, several peptides post-translational modifications of preproghrelin generate several peptides with antithetical effects. Mol Cell Endocrinol 2006, 256(1-2):1-8.
77. Lall S., Tung L.Y., Ohlsson C., et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun 2001, 280(1):132-138.
78. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407(6806):908-913.
79. Hassouna R., Zizzari P., Tolle V. The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake. J Neuroendocrinol 2010, 22(7):793-804.
80. Dong X.Y., He J.M., Tang S.Q., et al. Is GPR39 the natural receptor of obestatin?. Peptides 2009, 30(2):431-438.
81. Gnanapavan S., Kola B., Bustin S.A., et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002, 87(6):2988.
82. Kierson J.A., Dimatteo D.M., Locke R.G., et al. Ghrelin and cholecystokinin in term and preterm human breast milk. Acta Paediatr 2006, 95(8):991-995.
83. Cassoni P., Papotti M., Ghe C., et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001, 86(4):1738-1745.
84. Jeffery P.L., Murray R.E., Yeh A.H., et al. Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr Relat Cancer 2005, 12(4):839-850.
85. Dossus L., McKay J.D., Canzian F., et al. Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Carcinogenesis 2008, 29(7):1360-1366.
86. Tschop M., Weyer C., Tataranni P.A., et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50(4):707-709.
87. Cummings D.E., Weigle D.S., Frayo R.S., et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002, 346(21):1623-1630.
88. Zhang N., Yuan C., Li Z., et al. Meta-analysis of the relationship between obestatin and ghrelin levels and the ghrelin/obestatin ratio with respect to obesity. Am J Med Sci 2011, 341(1):48-55.
89. Vicennati V., Genghini S., De Iasio R., et al. Circulating obestatin levels and the ghrelin/obestatin ratio in obese women. Eur J Endocrinol 2007, 157(3):295-301.
90. Manabe Y., Toda S., Miyazaki K., et al. Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol 2003, 201(2):221-228.
91. Iyengar P., Espina V., Williams T.W., et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005, 115(5):1163-1176.
92. Kim K.Y., Baek A., Park Y.S., et al. Adipocyte culture medium stimulates invasiveness of MDA-MB-231 cell via CCL20 production. Oncol Rep 2009, 22(6):1497-1504.
93. Martin L.J., Boyd N.F. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008, 10(1):201.
94. Hu Y., Ghosh S., Amleh A., et al. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 2005, 24(56):8343-8348.
95. Passaperuma K., Warner E., Hill K.A., et al. Is mammographic breast density a breast cancer risk factor in women with BRCA mutations?. J Clin Oncol 2010, 28(23):3779-3783.
96. Johnston P.G., Rondinone C.M., Voeller D., et al. Identification of a protein factor secreted by 3T3-L1 preadipocytes inhibitory for the human MCF-7 breast cancer cell line. Cancer Res 1992, 52(24):6860-6865.
97. Chamras H., Bagga D., Elstner E., et al. Preadipocytes stimulate breast cancer cell growth. Nutr Cancer 1998, 32(2):59-63.
98. Bjorbaek C., Uotani S., da Silva B., et al. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997, 272(51):32686-32695.
99. Phrakonkham P., Viengchareun S., Belloir C., et al. Dietary xenoestrogens differentially impair 3T3-L1 preadipocyte differentiation and persistently affect leptin synthesis. J Steroid Biochem Mol Biol 2008, 110(1-2):95-103.
100. Simon P.A., Frye D.M. Obesity and longevity. N Engl J Med 2005, 352(24):2555. [author reply: 2556-7].
101. Smith-Kirwin S.M., O'Connor D.M., De Johnston J., et al. Leptin expression in human mammary epithelial cells and breast milk. J Clin Endocrinol Metab 1998, 83(5):1810-1813.
102. Ahima R.S., Prabakaran D., Mantzoros C., et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996, 382(6588):250-252.
103. Weigle D.S., Bukowski T.R., Foster D.C., et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest 1995, 96(4):2065-2070.
104. Montague C.T., Farooqi I.S., Whitehead J.P., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387(6636):903-908.
105. Considine R.V., Caro J.F. Leptin in humans: current progress and future directions. Clin Chem 1996, 42(6 Pt 1):843-844.
106. Maffei M., Halaas J., Ravussin E., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1(11):1155-1161.
107. Dieudonne M.N., Machinal-Quelin F., Serazin-Leroy V., et al. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2002, 293(1):622-628.
108. Lautenbach A., Budde A., Wrann C.D., et al. Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells. Nutr Cancer 2009, 61(4):484-491.
109. Naviglio S., Di Gesto D., Illiano F., et al. Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells. J Cell Physiol 2010, 225(3):801-809.
110. Jiang H., Yu J., Guo H., et al. Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. Biochem Biophys Res Commun 2008, 368(1):1-5.
111. Gonzalez-Perez R.R., Xu Y., Guo S., et al. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell Signal 2010, 22(9):1350-1362.
112. Ren H., Zhao T., Wang X., et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2010, 394(1):59-63.
113. Soma D., Kitayama J., Yamashita H., et al. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J Surg Res 2008, 149(1):9-14.
114. Karaduman M., Bilici A., Ozet A., et al. Tissue leptin levels in patients with breast cancer. J BUON 2010, 15(2):369-372.
115. Ishikawa M., Kitayama J., Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004, 10(13):4325-4331.
116. Xia X.H., Gu J.C., Bai Q.Y., et al. Overexpression of leptin and leptin receptors in breast cancer positively correlates with clinicopathological features. Chin Med J (Engl) 2009, 122(24):3078-3081.
117. Jarde T., Caldefie-Chezet F., Damez M., et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep 2008, 19(4):905-911.
118. Hancke K., Grubeck D., Hauser N., et al. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res Treat 2010, 119(2):367-377.
119. Falk R.T., Brinton L.A., Madigan M.P., et al. Interrelationships between serum leptin, IGF-1, IGFBP3, C-peptide and prolactin and breast cancer risk in young women. Breast Cancer Res Treat 2006, 98(2):157-165.
120. Petridou E., Papadiamantis Y., Markopoulos C., et al. Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control 2000, 11(5):383-388.
121. Stattin P., Soderberg S., Biessy C., et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat 2004, 86(3):191-196.
122. Teras L.R., Goodman M., Patel A.V., et al. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009, 18(9):2553-2557.
123. Cleveland R.J., Gammon M.D., Long C.M., et al. Common genetic variations in the LEP and LEPR genes, obesity and breast cancer incidence and survival. Breast Cancer Res Treat 2010, 120(3):745-752.
124. Terrasi M., Fiorio E., Mercanti A., et al. Functional analysis of the -2548G/A leptin gene polymorphism in breast cancer cells. Int J Cancer 2009, 125(5):1038-1044.
125. Liu C.L., Chang Y.C., Cheng S.P., et al. The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology 2007, 72(1-2):75-81.
126. Diez J.J., Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003, 148(3):293-300.
127. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423(6941):762-769.
128. Pfeiler G.H., Buechler C., Neumeier M., et al. Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 2008, 19(3):787-793.
129. Kern P.A., Di Gregorio G.B., Lu T., et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52(7):1779-1785.
130. Miyoshi Y., Funahashi T., Kihara S., et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003, 9(15):5699-5704.
131. Shahar S., Salleh R.M., Ghazali A.R., et al. Roles of adiposity, lifetime physical activity and serum adiponectin in occurrence of breast cancer among Malaysian women in Klang Valley. Asian Pac J Cancer Prev 2010, 11(1):61-66.
132. Chen D.C., Chung Y.F., Yeh Y.T., et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006, 237(1):109-114.
133. Mantzoros C., Petridou E., Dessypris N., et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004, 89(3):1102-1107.
134. Korner A., Pazaitou-Panayiotou K., Kelesidis T., et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007, 92(3):1041-1048.
135. Gaudet M.M., Falk R.T., Gierach G.L., et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?. Cancer Epidemiol 2010, 34(5):580-586.
136. Dos Santos E., Benaitreau D., Dieudonne M.N., et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 2008, 20(4):971-977.
137. Saxena N.K., Sharma D. Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr 2010, 4(3):358-362.
138. Jarde T., Caldefie-Chezet F., Goncalves-Mendes N., et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009, 16(4):1197-1210.
139. Arditi J.D., Venihaki M., Karalis K.P., et al. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 2007, 39(1):9-13.
140. Taliaferro-Smith L., Nagalingam A., Zhong D., et al. LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 2009, 28(29):2621-2633.
141. Bell L.N., Ward J.L., Degawa-Yamauchi M., et al. Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab 2006, 291(4):E843-E848.
142. Rehman J., Considine R.V., Bovenkerk J.E., et al. Obesity is associated with increased levels of circulating hepatocyte growth factor. J Am Coll Cardiol 2003, 41(8):1408-1413.
143. Rahimi N., Saulnier R., Nakamura T., et al. Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted by adipocytes. DNA Cell Biol 1994, 13(12):1189-1197.
144. Sheen-Chen S.M., Liu Y.W., Eng H.L., et al. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(3):715-717.
145. Ruan H., Lodish H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003, 14(5):447-455.
146. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17(1):4-12.
147. Guerrero J., Tobar N., Caceres M., et al. Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-beta1 and TNF-alpha. Breast Cancer Res Treat 2010, 119(2):497-508.
148. Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998, 22(12):1145-1158.
149. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998, 83(3):847-850.
150. Bachelot T., Ray-Coquard I., Menetrier-Caux C., et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003, 88(11):1721-1726.
151. Grano M., Mori G., Minielli V., et al. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts. Biochem Biophys Res Commun 2000, 270(3):1097-1100.
152. Slattery M.L., Curtin K., Sweeney C., et al. Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity (Silver Spring) 2008, 16(2):339-347.
153. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8(12):915-928.
154. Maor S., Mayer D., Yarden R.I., et al. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 2006, 191(3):605-612.
155. Surmacz E., Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res 2004, 23(3):385-394.
156. Yee D., Lee A.V. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000, 5(1):107-115.
157. Oesterreich S., Zhang P., Guler R.L., et al. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 2001, 61(15):5771-5777.
158. Yu W., Gu J.C., Liu J.Z., et al. Regulation of estrogen receptors alpha and beta in human breast carcinoma by exogenous leptin in nude mouse xenograft model. Chin Med J (Engl) 2010, 123(3):337-343.
159. Fusco R., Galgani M., Procaccini C., et al. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer 2010, 17(2):373-382.
160. Binai N.A., Damert A., Carra G., et al. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int J Cancer 2010, 127(1):55-66.
161. Catalano S., Marsico S., Giordano C., et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 2003, 278(31):28668-28676.
162. Maskarinec G., Woolcott C., Steude J.S., et al. The relation of leptin and adiponectin with breast density among premenopausal women. Eur J Cancer Prev 2010, 19(1):55-60.
163. Maccio A., Madeddu C., Gramignano G., et al. Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. J Mol Med 2010, 88(7):677-686.
164. Saxena N.K., Taliaferro-Smith L., Knight B.B., et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res 2008, 68(23):9712-9722.
165. Purohit A., Newman S.P., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002, 4(2):65-69.
166. Suarez-Cuervo C., Harris K.W., Kallman L., et al. Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat 2003, 80(1):71-78.
167. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
168. John E.M., Horn-Ross P.L., Koo J. Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev 2003, 12(11 Pt 1):1143-1152.
169. Matthews C.E., Shu X.O., Jin F., et al. Lifetime physical activity and breast cancer risk in the Shanghai Breast Cancer Study. Br J Cancer 2001, 84(7):994-1001.
170. Ueji M., Ueno E., Osei-Hyiaman D., et al. Physical activity and the risk of breast cancer: a case-control study of Japanese women. J Epidemiol 1998, 8(2):116-122.
171. Yang D., Bernstein L., Wu A.H. Physical activity and breast cancer risk among Asian-American women in Los Angeles: a case-control study. Cancer 2003, 97(10):2565-2575.
172. King M.C., Marks J.H., Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302(5645):643-646.
173. Abrahamson P.E., Gammon M.D., Lund M.J., et al. Recreational physical activity and survival among young women with breast cancer. Cancer 2006, 107(8):1777-1785.
174. Holick C.N., Newcomb P.A., Trentham-Dietz A., et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(2):379-386.
175. Irwin M.L., Mayne S.T. Impact of nutrition and exercise on cancer survival. Cancer J 2008, 14(6):435-441.
176. Sternfeld B., Weltzien E., Quesenberry C.P., et al. Physical activity and risk of recurrence and mortality in breast cancer survivors: findings from the LACE study. Cancer Epidemiol Biomarkers Prev 2009, 18(1):87-95.
177. Chlebowski R.T., Blackburn G.L., Thomson C.A., et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006, 98(24):1767-1776.
178. Hoy M.K., Winters B.L., Chlebowski R.T., et al. Implementing a low-fat eating plan in the Women's Intervention Nutrition Study. J Am Diet Assoc 2009, 109(4):688-696.
179. Pierce J.P., Natarajan L., Caan B.J., et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007, 298(3):289-298.
180. Ligibel J.A., Giobbie-Hurder A., Olenczuk D., et al. Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes Control 2009, 20(8):1523-1528.
181. Irwin M.L. Physical activity interventions for cancer survivors. Br J Sports Med 2009, 43(1):32-38.
182. Ligibel J.A., Campbell N., Partridge A., et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 2008, 26(6):907-912.
183. Miller W.R. Aromatase inhibitors and breast cancer. Minerva Endocrinol 2006, 31(1):27-46.
184. Haynes B.P., Straume A.H., Geisler J., et al. Intratumoral estrogen disposition in breast cancer. Clin Cancer Res 2010, 16(6):1790-1801.
185. Dunbier A.K., Anderson H., Ghazoui Z., et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol 2010, 28(7):1161-1167.
186. Ellis M.J., Miller W.R., Tao Y., et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat 2009, 116(2):371-378.
187. Sachdev D., Zhang X., Matise I., et al. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 2010, 29(2):251-262.
188. Helle S.I., Holly J.M., Tally M., et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996, 69(4):335-339.
189. Pollak M.N., Huynh H.T., Lefebvre S.P. Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 1992, 22(1):91-100.
190. Lisztwan J., Pornon A., Chen B., et al. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res 2008, 10(4):R56.
191. Wolf I., Sadetzki S., Catane R., et al. Diabetes mellitus and breast cancer. Lancet Oncol 2005, 6(2):103-111.
192. Richardson L.C., Pollack L.A. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005, 2(1):48-53.
193. Goodwin P.J., Stambolic V., Lemieux J., et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011, 126(1):215-220.
194. Jalving M., Gietema J.A., Lefrandt J.D., et al. Metformin: taking away the candy for cancer?. Eur J Cancer 2010, 46(13):2369-2380.
195. Otvos L., Kovalszky I., Scolaro L., et al. Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. Peptide Science 2011, 96:117-125.
196. Rene Gonzalez R., Watters A., Xu Y., et al. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res 2009, 11(3):R36.
197. Terry M.B., Gammon M.D., Zhang F.F., et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004, 291(20):2433-2440.
198. Zhang Y., Coogan P.F., Palmer J.R., et al. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005, 162(2):165-170.
199. Garcia Rodriguez L.A., Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004, 91(3):525-529.
200. DuBois R.N. Aspirin and breast cancer prevention: the estrogen connection. JAMA 2004, 291(20):2488-2489.
201. Harvie M., Howell A. Energy balance adiposity and breast cancer-energy restriction strategies for breast cancer prevention. Obes Rev 2006, 7(1):33-47.